Gastroesophageal-junction Cancer Clinical Trial
Official title:
A Single-center, Prospective, Single-arm Clinical Study of Laparoscopic Proximal Gastrectomy Based on an Original Esophagogastric Anastomose (PTST,Parachute- Tunnel- Style Technique)
1. To evaluate the safety, simplicity and effectiveness of the gastric function (anti-reflux) preservation of the innovative "parachute-tunnel-style technique" (PTST) in laparoscopic proximal gastrectomy. 2. To investigate the correlation between anastomotic stenosis and blood supply of serosa-muscle flap,suture after esophagogastric anastomosis.(obtain objective indexes such as blood supply, healing pattern and length change of serosa-muscle flap through animal experiments)
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05872295 -
IKS014 in Advanced Solid Tumors That Express HER2
|
Phase 1 | |
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Not yet recruiting |
NCT06093425 -
Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
|
Phase 3 | |
Recruiting |
NCT04396821 -
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03526835 -
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02085564 -
Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer
|
N/A | |
Recruiting |
NCT05494060 -
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05687357 -
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05447234 -
TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
|
Early Phase 1 | |
Recruiting |
NCT05439993 -
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05480384 -
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
|
Phase 2 | |
Recruiting |
NCT05858736 -
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06121700 -
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05608785 -
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
|
Phase 1/Phase 2 | |
Recruiting |
NCT05539430 -
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
|
Phase 1 |